– The full-phase clinical study paves the way for the application for approval
Healthcare answers provider Global Response Aid (GRA) and Dr. Reddy’s Laboratories (NYSE: RDY) announced that the antiviral drug Avigan (R) had produced promising effects in a single-blind, placebo-controlled phase 3 clinical trial conducted in Japan with sponsorship. from FujiFilm Toyama Chemical.
Patients receiving Avigan (R) recovered from COVID-19 symptoms 2. 8 days earlier, on average, compared to the group. Research showed that statistically patients were more likely to recover statistically when given Avigan (R) compared to patients who did not receive the drug.
The test focused on 156 hospitalized patients with COVID-19-induced pneumonia, and was divided into two teams or “arms”. Patients on the first arm won Avigan (R). Patients at the time in the arm gained a placebo for the drug. The percentage of patients in avigan (R) showed immediate relief in viral load.
The goal of the test to measure the cure of pneumonia and symptoms of COVID-19. Monitored patient temperature, oxygen saturation, and CT scans of the lungs. The time to relieve symptoms measured between the first administration of the drug (or placebo). and the time when SARS-COV-2-induced symptoms have become undetectable.
Shortening recovery time reduces the threat of headaches in patients and, more importantly, particularly reduces the threat of a patient spreading the virus. The most recent findings open up the option of treating patients with mild to moderate cases of COVID-19 on an outpatient basis. which can also delay the spread of the pandemic.
Avigan (R), comprising the active element Favipiravir, evolved through FujiFilm Toyama Chemical in the 1990s as an anti-flu drug. GRA, Dr. Reddy’s Laboratories and FujiFilm Toyama recently signed a global licensing agreement covering the production, marketing and distribution of Avigan (R).
The effects of the trial in Japan recommend the efficacy of Avigan (R) as a remedy to prevent patients with COVID-19 from going from a mild clinical level to a more severe or critical level of the disease, and to enhance the healing effect. COVID-19 symptoms.
GRA CEO Mitch Wilson said the FujiFilm Toyama exam represents a breakthrough in the fight against COVID-19 and paves the way for Avigan (R) to be approved as a remedy against COVID-19 in Japan. Array The drug is already approved in India, Russia, Indonesia and other countries around the world.
“The effects of this university-led study are evidence that we all want to combat this pandemic,” Wilson said. “We are actively working with regulators to accelerate approval in key markets. Because Avigan (R) is manufactured as a tablet, the drug can be self-administered at home, reducing the burden on patients in hospitals and medical staff. In addition, Avigan (R) requires refrigerated shipping or garage, which greatly facilitates the immediate distribution of the drug in countries and markets with few garage infrastructure. “
Avigan (R) is the subject of clinical trials in PATIENTS with COVID-19 in several countries and has been used to treat patients with COVID-19 in studies conducted in China’s Hubei Province, conducted through the China-Japan Friendship Hospital. It is being tested in the United States as part of a Multi-Site Phase 2 exam involving first inpatients, a trial sponsored by FujiFilm Toyama Chemical. It is also the subject of a Phase 2 exam initiated through researchers on topics with or asymptomatic COVID-19 conducted through Stanford University School of Medicine.
Avigan (R) Tablet was approved for manufacture and sale in Japan in 2014 as an antiviral drug opposed to influenza. The use of the drug should only be considered as in the event of an outbreak of new or re-emergency influenza virus infections in which other antiviral influenza drugs are not effective or not effective enough and the Japanese government makes the decision to use the drug as a countermeasure to oppose those influenza viruses.
GRA is a Dubai-based company created through the world leader in Agility Logistics (KSE: AGLTY) and AiPHARMA, a biotechnology company to acquire and expand qualified diagnostic, testing and coverage products and facilities used in the detection, repair and prevention of COVID-19 and other threats to public fitness.
About Global Response Help (GRA)
Global Response Aid, founded in Dubai, provides answers to public fitness challenges. GRA was created through Agility, a world leader in logistics, and AiPHARMA, a biotechnology company, to acquire and expand qualified diagnostic, verification and protection products and facilities used in the detection, repair and prevention of COVID-19 and other public health threats. . GRA works with trusted brands to locate safe and effective products for governments, fitness governance and public institutions; frontline medical facilities; The song; corporations that seek to protect staff and workplaces. GRA products come with fans, thermal sensing equipment, thermometers, masks, goggles, protective suits, nitrile gloves, cleaning and disinfection products and point-of-care control kits. Servicio. La GRA cell phone app helps prevent virus spread by using touch tracking and network alerts. GRA is also deploying self-celled cell diagnostic verification and trained groups that perform COVID-19 verification in schools and workplaces. For more information, visit https://globalresponseaid. com/
About FUJIFILM
FUJIFILM Toyama Chemical Co. , Ltd. conducts research, progress, manufacture and sale of radiopharmaceuticals and small molecule pharmaceuticals. In close cooperation with FUJIFILM Corporation, it aims to expand cutting-edge diagnostic and curative radiopharmaceuticals as well as curative drugs with unique mechanisms of action in the fields of “oncology”, “diseases of the central nervous system formula” and ” Infectious diseases “where doctors want. still exists. It is also working on the progression of new drugs that employ drug delivery formulations (DDS) technologies, designed to deliver the required amount of drug at the right time to the fast box area. By exploring synergy with in vitro diagnostic devices and reagents owned by Fujifilm organization companies, the company will expand its offering of complete solutions, from diagnostics to treatment. FUJIFILM Toyama Chemical has expanded its commercial spaces to medical IoT solutions, adding a formula to help pharmacists perform drug distribution audits and a shipping device that enables strict temperature control suitable for blood products Cell Array and tissues used for regenerative medicine. Through the progression and source of new high-quality, high-value-added drugs and products that help clinical settings, FUJIFILM Toyama Chemical strives to solve various social, assistive medicine and quality challenges. of life. please stop at http://fftc. fujifilm. co. jp/en/
About Dr. Reddy’s
Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is a built-in pharmaceutical company committed to providing affordable, cutting-edge medicines for healthier living. Through its 3 activities: pharmaceuticals and active ingredients Services, Global Generics and Exclusive Products – Dr. Reddy’s offers a portfolio of products and addition of APIs, customized pharmaceutical generics, biosimilars and differentiated formulations Our main healing spaces are: gastrointestinal, cardiovascular, diabetic, oncology, pain control and dermatology. Reddy’s operates in markets around the world. Our main markets are the United States, India, Russia, CiS countries and Europe. For more information, visit: www. drreddys. com
About AiPharma
AiPHARMA is a newly created biotechnology company with regional offices in Boston, Dubai, Tokyo, Singapore and Hong Kong. Aipharma brings a highly interdisciplinary technique to science, with facilities founded on the paintings of leading university laboratories in biophysics and algorithmic design that drive life science studies and progression to human health The company leverages device learning and automation to create large-scale scientific platforms based on engineering disciplines , the company’s platform technologies vertically integrate patented hardware, software, bioinformatics, chemistry and molecular biology to advance fundamental studies, goal validation and clinical trials.
About Agility
Agility is a global logistics company with annual sales of $5. 2 billion and more than 26,000 workers in more than a hundred countries. It is one of the world’s leading suppliers of contract logistics and cargo shipping services, and a leader and investor in the generation-to-source chain. Agility is a pioneer in emerging markets and one of the largest owners and developers of warehouses and advertising parks in the Middle East, Africa and Asia. Agility’s subsidiaries offer fuel logistics, airport services, real estate advertising and facility management. customs digitization services and remote infrastructure. For more information about Agility, visit www. agility. com
Twitter: twitter. com/agilityLinkedIn: linkedin. com/company/agility YouTube: youtube. com/user/agilitycorp
Forward-Looking: This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to dangers, uncertainties and other points, adding the option of adverse clinical trials involving Avigan (R) and the option that we may not be able to complete one or more of those tests within the recently scheduled time frame or not complete at all. Furthermore, it is conceivable that GRA and Dr. Reddy’s will make a strategic resolution to disrupt Avigan’s progression (R). As a result, Avigan (R) may never advertise properly. All messages other than old events are messages that can also be considered future messages. These dangers, uncertainties and other points can also cause the actual effects to differ materially from those discussed in the prospectuses. The reader is cautioned not to rely on these prospects. These and other dangers are described in detail in Dr. Reddy’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the United States Securities and Exchange Commission. All forward-looking emails are based on data currently held by GRA, and GRA assumes no legal responsibility to update such emails for the future.
เพี ย คุ ใช้ อี เม ขอ คุ เอ ก็ สา มา คุ เอ คุ เอ ถ ส่ ข่าว ด้ โดย ป ที่ ด้ โดย น้า ฝา ข่าว ป ชา สั ม พั ชา สั ม พัา’ ติด ปัญชา สั พั ธ์ ธ์ มาา รีา สา ถ ติดต่อ เา ด้ ที่ น้า fan page ThaiPR. net รือ อี เม ชา สั ม พัา เชา สั ม พัา ที่ help@thaipr. net ขอบคุ ค่ ‘fan page า ที่ help@thaipr. net ขอบคุ ค่’ ชา สั ม พั ‘า ที่ help@thaipr. net ขอบคุ ค่